Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders

Sara Hall; Shorena Janelidze; Henrik Zetterberg; Britta Brix; Niklas Mattsson; Yulia Surova; Kaj Blennow; Oskar Hansson

doi:10.1002/mds.27950

Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders

Mov Disord. 2020 Mar;35(3):513-518. doi: 10.1002/mds.27950. Epub 2019 Dec 13.

Authors

Sara Hall^{1

2}, Shorena Janelidze¹, Henrik Zetterberg^{3

4

5

6}, Britta Brix⁷, Niklas Mattsson^{1

8

9}, Yulia Surova^{1

8}, Kaj Blennow^{4

5}, Oskar Hansson^{1

2}

Affiliations

¹ Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.
² Memory Clinic, Skåne University Hospital, Malmö, Sweden.
³ Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
⁴ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Mölndal, Sweden.
⁵ Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
⁶ UK Dementia Research Institute at UCL, London, United Kingdom.
⁷ EUROIMMUN AG, Luebeck, Germany.
⁸ Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden.
⁹ Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.

PMID: 31837067
DOI: 10.1002/mds.27950

Abstract

Background: CSF concentration of neurogranin has been suggested as a biomarker for synapse dysfunction.

Objectives: To investigate CSF neurogranin in parkinsonian disorders compared to controls and Alzheimer's disease and the possible correlations between neurogranin and cognitive and motor impairment.

Methods: We included 157 patients with PD, 29 with PD with dementia, 11 with dementia with Lewy bodies, 26 with MSA, 21 with PSP, 6 with corticobasal syndrome, 47 controls, and 124 with Alzheimer's disease. CSF neurogranin was measured using two enzyme-linked immunosorbent assays; from EUROIMMUN and the University of Gothenburg.

Results: We found a strong correlation between CSF neurogranin-EI and CSF neurogranin-University of Gothenburg (R_s = 0.890; P < 0.001). Neurogranin was decreased in PD, PD with dementia, MSA, and PSP compared to controls and Alzheimer's disease. Neurogranin did not correlate with motor or cognitive impairment, longitudinal decline, or progression to dementia in PD.

Conclusions: CSF neurogranin is decreased in parkinsonian disorders compared to controls, emphasizing the importance of synaptic dysfunction in these disorders. © 2019 International Parkinson and Movement Disorder Society.

Keywords: cerebrospinal fluid; neurogranin; parkinsonian disorders.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Alzheimer Disease* / diagnosis
Biomarkers / cerebrospinal fluid
Cognitive Dysfunction* / diagnosis
Humans
Neurogranin / cerebrospinal fluid*
Parkinsonian Disorders* / diagnosis

Substances

Biomarkers
Neurogranin